23 results about "Conglutination reaction" patented technology

The invention provides a solid-phase agglutination detection test paper card and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a cell carrying a specific antigen or a conjugate formed by coupling the specific antigen and an inert carrier, and the granular antigen can be colored or has a luminescence property in various modes. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.

The invention provides a solid-phase agglutination detection test paper card directly marked by antigens and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a conjugate formed by coupling a specific antigen and an inert carrier, the specific antigen is not a protein, and the specific antigen is specifically combined with an antibody to be detected. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.

The invention relates to a syphilis non-specific antibody detection result automatic interpretation method and system, and belongs to the technical field of biomedical detection. The method comprises the following steps: acquiring a sample image after agglutination reaction through shooting equipment, and transmitting the sample image to an automatic interpretation system through a wireless network; the system preprocesses the image, extracts morphological features, distribution features and texture features of agglutination particles by using a pre-trained AI model, and fuses metadata such as patient age and detection time to generate a fusion feature vector; performing similarity matching with a historical sample database based on the feature vector, and automatically interpreting a result through a weighting rule engine; and the interpretation result is output in a differentiated visual form, and the subjectivity of manual interpretation is eliminated and the problem of inconsistent results is solved through a unified image preprocessing and feature extraction method.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The application discloses a duck Riemerella anatipestifer (RA) surface adhesion factor 3-glyceraldehyde-3-phosphate dehydrogenase protein (GAPDH) conservative B cell epitope peptide, a nucleic acid molecule, a recombinant carrier and application thereof. The application inserts the conservative B cell epitope TG12 into chicken white dysentery Salmonella Peg fimbria, introduces the inert carrier bacteria, and obtains the recombinant bacteria which can functionally express and present the RaGAPDH protein surface conservative B cell epitope peptide. The expression and presentation of the conservative B cell epitope can specifically recognize and combine duck and goose RA infection serum, and the naked-eye visible agglutination reaction particles are observed, and there is no cross agglutination reaction with other pathogen infection positive serum. The agglutination detection method has the advantages of specificity and convenience, and is expected to provide a new idea and method for detection and prevention and control of RA infection.

The application discloses a red blood cell adhesion enhancer, wherein 1000 mL of the red blood cell adhesion enhancer comprises the following components: 0.5-2.0 g of sodium chloride, 2.0-5.0 g of disodium ethylenediaminetetraacetate, 1.0-3.0 g of sodium citrate, and the rest is ultrapure water. The red blood cell adhesion enhancer and the cell suspension of washed human packed red blood cells can be used for preparing a solid-phase agglutination reaction microplate. Compared with a traditional "normal saline-red blood cell" suspension, the cell suspension constructed by the red blood cell adhesion enhancer and the human packed red blood cells can significantly increase the number of red blood cells adhered to the surface of a solid-phase microplate carrier, ensure the sufficient and stable number of adhered red blood cell antigens in a long-term storage process of the solid-phase microplate, ensure the number of red blood cell antigens reacted with a to-be-tested antibody, improve the sensitivity of the solid-phase agglutination reaction, avoid false negatives caused by missed detection of the same antibody, and reduce the risk of blood transfusion.

The invention discloses a platelet antibody detection kit and application thereof. Belongs to the technical field of detection kits. The kit comprises a microcolumn gel card, an enzyme-labeled secondary antibody, an enzyme-labeled secondary antibody diluent, a 20x washing solution, a developing solution, a fresh platelet treatment solution, a platelet buffer solution, a platelet preparation solution, a freeze-dried platelet reconstitution fluid, freeze-dried platelets and a negative control. The platelet antibody detection kit disclosed by the invention has the beneficial effects that the platelet antibody detection kit disclosed by the invention enables cross-matching of platelets to be possible; according to the invention, a micro-column gel immunoassay technology is combined with an enzyme immunolabeling technology, so that the limitation that only agglutination reaction can be carried out in a micro-column gel method is solved; according to the reaction card washing equipment disclosed by the invention, semi-automatic operation of micro-column gel method detection is realized; in the plasma, triglyceride is less than or equal to 5mg / mL, bilirubin is less than or equal to 20mg / dL, and hemoglobin is less than or equal to 5mg / mL, so that the result is not influenced; the kit has the advantages of good stability, long effective period, high sensitivity, strong specificity and simple operation.

The invention belongs to the technical field of medicine quality detection, and particularly relates to a method for detecting bacterial endotoxin of a raw material medicine in bromhexine hydrochloride injection. According to the method, a mode of heating and dissolving the hydrochloric acid solution with the pH value of 4.0 is adopted, and the 001 * 7 type cation exchange resin microcolumn purification is combined, so that the inhibition effect of cation impurities in the raw material medicine on agglutination reaction of the tachypleus amebocyte lysate can be effectively eliminated, and a stable and uniform test solution is prepared. According to the process, the minimum non-interference dilution multiple is obviously reduced to 160 times, and the operation error and the detection sensitivity loss caused by high-multiple dilution are reduced. As the dilution ratio is greatly reduced, a tachypleus amebocyte lysate with the sensitivity of 0.25 EU.mL <-1 > can be selected in the method. Compared with a high-sensitivity reagent needed in the prior art, the reagent of the specification is easier to purchase and lower in cost, solves the problems that the high-sensitivity reagent is large in daily purchase difficulty and high in price, and is more suitable for conventional application in industrial quality control.

The utility model discloses a test tube convenient for observing the agglutination degree of an immune test, which is applied to the technical field of medical instruments, ensures that the distribution of agglutinates at each angle can be stably observed through 360-degree dead-angle-free observation, keeps stable in rotation operation, avoids overturning of a sample, and is simple in structure and convenient to operate. The incident angle of ambient light can be adjusted to the optimal reflection range by the 45-degree inclination angle, so that the light forms a light and shade contrast enhancement effect on the surface of the agglutinant, the micro agglutination reaction is convenient to identify, and the projection of the agglutinant particles can be amplified to the optimal resolution size of human eyes; the top opening of the standard cylindrical tube body is smooth and round, the tube opening is thickened, the bottom transition is oblate, 20% of the upper surface of the outer surface of the tube body is frosted, and the remaining 80% of the outer surface of the tube body is transparent, so that the agglutination degree of an immune test can be observed more favorably; 20% of the upper surface of the tube body is frosted, so that the tube body is convenient to pick and is not easy to slip; liquid in the tube is not easy to pour out when the tube opening is thickened and inclined; and the pollution probability of the laboratory is reduced.

A disposable blood typing device is provided for determining ABO and RhD blood types using binary logic-based interpretation. The device includes a sample application area, test zones containing dried anti-A, anti-B, and optionally anti-D reagents, and a result output mechanism configured to display a binary outcome for each antigen. Binary values are assigned based on visible agglutination reactions, which are processed through a logical mapping structure—such as a printed chart, mechanical indicator, or electronic logic circuit—to determine the corresponding blood type. The device may incorporate visual indicators, control regions, waste containment, and optional digital components for electronic display or wireless data transmission. Designed for single use, the system facilitates self-administered or point-of-care testing without requiring clinical expertise, and may be integrated with mobile applications or health records systems. The invention enhances test accuracy, usability, and data interoperability while minimizing contamination risk and interpretation error.

A structurally intact red blood cell membrane, a preparation method therefor and the use thereof. Defining components of a release solution to lyse red blood cells allows for mild conditions, and can release protein components such as hemoglobin inside the red blood cells, remove cell properties thereof, keep the integrity of the cytoskeleton thereof and the activity of surface antigens of the membrane, and retain key blood group antigens on the surface of the red blood cell membrane while keeping the complete structure of the red blood cell membrane, thus reducing the problem of antigenicity reduction caused by fragmentation of the red blood cell membrane. After the red blood cells are lysed, nanoparticles are coupled to the surface of the red blood cell membrane, thus visualizing the agglutination reaction of the red blood cell membrane under the induction of antibodies. Using a fixed procedure to preserve engineered red blood cell biomembranes can effectively avoid damage to the engineered red blood cell biomembrane caused by ice crystals, ensure that the antigenicity of the membranes is not affected, allow for long-term preservation at room temperature, and prolong the shelf life to two years or more.

The application discloses a detection method for agglutination titer of yolk antibody of Vibrio parahaemolyticus of different serotypes and application thereof. The application determines the optimal conditions of agglutination reaction through screening of sample diluent, screening of bacterial liquid diluent and screening of reaction temperature; determines that there is no cross agglutination of yolk antibody of Vibrio parahaemolyticus of different serotypes through detection of cross reaction; evaluates the growth and decline law of titer of yolk antibody of Vibrio parahaemolyticus; and the detection method is simple in operation, is helpful to solve the problem of effect evaluation of yolk antibody of Vibrio parahaemolyticus, and lays a foundation for popularization and application of yolk antibody of Vibrio parahaemolyticus.

The application discloses a chicken salmonella pullorum strain stably expressing variant O antigen and a construction method and application thereof, and constructs an expression plasmid containing a J23119 promoter and a SPUL_2404 gene, and then the expression plasmid is transferred into chicken salmonella pullorum, so that a chicken salmonella pullorum strain overexpressing the SPUL_2404 gene is constructed to stably express the variant O antigen, and agglutination test shows that the strain only has a typical agglutination reaction with chicken salmonella pullorum variant serums, and does not have a typical agglutination reaction with chicken salmonella pullorum standard serums, and after subculture, O antigens of all subclone colonies are stable, and only have a typical agglutination reaction with the variant serums, so that the strain can be used for preparing chicken salmonella pullorum variant agglutination antigens.

Disclosed are fusion proteins for the prevention of false positive agglutination as well as methods of production, uses and kits thereof.

The invention provides preparation of a novel O antigen and specific serum of vibrio parahaemolyticus. The classification name of the vibrio parahaemolyticus is vibrio parahaemolyticus O17: K4, and the preservation number of the vibrio parahaemolyticus O17: K4 is CGMCC (China General Microbiological Culture Collection Center) No.31706. The invention further discloses a preparation method of the vibrio The novel thallus antigen O17 vibrio parahaemolyticus is determined by adopting an agglutination reaction and a whole genome sequencing method of existing diagnostic serum (11 kinds of O) of the vibrio parahaemolyticus. The novel O17 specific serum is obtained through preparation of a novel thallus antigen O17, animal immunization and adsorption separation. The novel O17 specific serum prepared by the invention is high in sensitivity and strong in specificity, can be conveniently and quickly used for detecting a brand new novel thallus antigen O17 vibrio parahaemolyticus which is prevalent in recent years, and provides an important detection technology for pathogen confirmation, monitoring and prevention and control of infectious diarrhea and food-borne diseases in laboratories.

The invention discloses an agglutination-labeled complement C1q binding reaction (A-LCFA) detection technical method based on fusion agglutination reaction and labeled complement C1q binding reaction and application of the A-LCFA detection technical method. According to the method, high simplicity and convenience of the agglutination reaction are combined with high specificity of the complement C1q binding reaction and high sensitivity of a labeling technology; the efficient detection of the target antibody or antigen is realized. The method comprises the following specific steps: reacting a granular antigen or antibody with a sample to be detected to form an agglutination complex, adding a complement C1q binding antigen-antibody complex, and carrying out signal detection by marking a complement C1q antibody. The method is suitable for the field of immunological antibody or antigen detection, and has the characteristics of simplicity and convenience in operation, high specificity and high sensitivity. The embodiment shows successful application of the Brucella antibody detection kit in Brucella antibody detection, and the Brucella antibody detection kit comprises a plate agglutination mode and a column agglutination mode. The technology provides a new solution for immunological detection, and has remarkable practical value and popularization potential.

The present invention relates to an antibody or antigen-binding fragment thereof that specifically binds to porcine Y sperm, a composition comprising same, and use thereof. It was confirmed that treatment with the antibody or an antigen-binding fragment thereof, of the present invention, induced an aggregation reaction of Y chromosome sperm, thereby enabling easy distinction between X chromosome sperm and the Y chromosome sperm. Thus, pigs having a specific sex can be mass-produced, and pigs having a desired sex can be selectively produced, thereby contributing to planned breeding, breeding improvement, and management efficiency.

The invention discloses a magnetic hydrothermal carbon material reversely wrapped by an unmarked cell membrane as well as a preparation method and application of the magnetic hydrothermal carbon material, magnetic carbon nanospheres are prepared by a hydrothermal method, and then carboxyl groups on the surfaces of the magnetic carbon nanospheres and residual amino groups of lectin such as concanavalin A are subjected to amide condensation, so that lectinized hydrothermal magnetic carbon nanospheres are obtained. Finally, agglutination reaction can be carried out on agglutinin and carbohydrate chains on the outer surface of the cell membrane, so that the cell membrane is wrapped from inside to outside. The biomimetic material can screen drugs acting on the inner side of a cell membrane, does not need to label the cell membrane, can reduce damage to membrane protein, provides a new technical means for deeply exploring lead compounds in natural products, and promotes development of traditional Chinese medicine anti-osteoporosis drugs. According to the invention, two novel potential anti-osteoporosis components targeting the inner surface of an osteoblast cell membrane in herba epimedii are successfully found.

The invention provides a red blood cell agglutination analysis method and application thereof in ABO blood type identification, the method comprises the following steps: mixing a red blood cell sample with an electrolyte solution, adding a red blood cell specific antibody to carry out agglutination reaction, adding the red blood cell solution subjected to agglutination reaction into a reaction tank of an electrochemical three-electrode system, obtaining a current-time curve through a timing current method; according to the current-time curve, obtaining the magnitude of the current of each section of step and the number of current steps so as to obtain collision step current, and according to the collision step current, judging whether the result of agglutination reaction between the erythrocyte sample and the erythrocyte specific antibody is agglutination or non-agglutination. According to the method, the agglutination degree is judged by observing the collision step current generated by collision of erythrocytes and the electrode, and the method is more visual and accurate. According to the method, the blood volume required by each time of detection is generally at a microliter (microliter) level, compared with a traditional method, the blood volume is reduced, the sensitivity of blood detection is improved, and the method can be used for quantitative immunoassay and blood type identification in medicine.

The invention provides a solid-phase agglutination detection test paper card for expressing a heterologous antigen by utilizing gene recombination and a detection method thereof. A reaction area of the solid-phase agglutination detection test paper card comprises a reaction film, the reaction film is coated with captured protein and can enrich to-be-detected antibodies in a to-be-detected sample, and the captured protein is combined with the to-be-detected antibodies and then subjected to agglutination reaction with granular antigens in a detection reagent to form an agglutination compound. And the agglutination compound is intercepted in the reaction film for color development. The granular antigen is a cell carrying a specific antigen, and the cell expresses and displays the specific antigen on the surface of the cell in a gene recombination mode. The solid-phase agglutination detection test paper card provided by the invention has the advantages of simple detection steps, short detection time, high sensitivity, accurate detection result, strong specificity and the like, can be used for detecting various diseases and monitoring antibody level, and also has important significance in the fields of infectious disease prevention and control, medical diagnosis and the like.

The present application relates to a kind of reagent and kit for rapid detection of blood group and purposes thereof, belong to blood group detection field.The reagent includes anti-A antigen nanobody, anti-B antigen nanobody and anti-RhD antigen nanobody.Based on the blood group detection reagent card prepared using the nanobody, blood group agglutination reaction is used to detect blood group in the sample to be measured, and the detection result can be observed in only 30s, and has the advantages of high sensitivity, low cost, storage resistance.

The invention provides a hybridoma cell strain capable of secreting an IgM (Immunoglobulin M) type monoclonal antibody of an anti-human I-type blood group antigen, the hybridoma cell strain is named as I4C4 and preserved in the China Center for Type Culture Collection on August 7, 2025, and the preservation number is CCTCC NO: C2025230. The invention also provides a monoclonal antibody secreted by the hybridoma cell strain secreting the IgM type monoclonal antibody of the anti-human I blood group antigen and application of the monoclonal antibody. An adult O-type red blood cell suspension is adopted as an antigen to immunize a BALB / c mouse, and the hybridoma cell strain I4C4 which can be stably passaged and secrete an anti-human I-type blood group antigen monoclonal antibody is obtained through immunization, cell fusion, screening and cloning. The monoclonal antibody secreted by the cell strain can generate macroscopic agglutination reaction with adult red blood cells, does not generate cell agglutination reaction with neonatal umbilical cord blood red blood cells, and is a monoclonal antibody cell strain secreting the anti-human I-type blood group antigen.

An object of the present invention is to provide a hemoglobin measurement reagent and measurement method that allow for more accurate measurement of the amount of hemoglobin by suppressing a decrease in a measured value of hemoglobin triggered by the addition of haptoglobin. The reagent for measuring hemoglobin of the present invention includes: an insoluble carrier immobilizing an anti-hemoglobin antibody; and an insoluble carrier immobilizing an anti-haptoglobin antibody. The method for measuring hemoglobin in a specimen of the present invention includes: a step (1) of mixing a specimen with haptoglobin and forming a hemoglobin-haptoglobin complex to obtain a sample containing the hemoglobin-haptoglobin complex; and a step (2) of bringing the sample obtained in the step (1) into contact with the insoluble carrier immobilizing an anti-hemoglobin antibody and the insoluble carrier immobilizing an anti-haptoglobin antibody to cause immunoagglutination.